Can Historical Financial Ratios
| CANF Stock | USD 1.54 0.03 1.91% |
Can Fite is presently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.3 or Days Sales Outstanding of 23.14 will help investors to properly organize and evaluate Can Fite Biopharma financial condition quickly.
Can |
About Can Financial Ratios Analysis
Can Fite BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Can Fite investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Can financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Can Fite history.
Can Fite Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Can Fite Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Can Fite sales, a figure that is much harder to manipulate than other Can Fite Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Can Fite's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Can Fite's Research And Ddevelopement To Revenue is most likely to drop in the upcoming years. The Can Fite's current Net Debt To EBITDA is estimated to increase to 0.78, while PTB Ratio is projected to decrease to 1.30.
| 2022 | 2024 | 2025 (projected) | Current Ratio | 3.66 | 4.41 | 3.69 | Net Debt To EBITDA | 0.29 | 0.6 | 0.78 |
Can Fite fundamentals Correlations
Click cells to compare fundamentals
Can Fite Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Can Fite fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 29.07 | 30.67 | 21.18 | 12.78 | 14.7 | 13.96 | |
| Ptb Ratio | 3.65 | 1.82 | 3.84 | 1.52 | 1.37 | 1.3 | |
| Book Value Per Share | 0.0169 | 0.026 | 0.005482 | 0.004883 | 0.005615 | 0.005335 | |
| Free Cash Flow Yield | (0.54) | (0.38) | (0.63) | (0.89) | (1.02) | (0.97) | |
| Operating Cash Flow Per Share | (0.0337) | (0.0178) | (0.0132) | (0.006601) | (0.005941) | (0.006238) | |
| Stock Based Compensation To Revenue | 0.47 | 0.55 | 0.32 | 0.35 | 0.4 | 0.52 | |
| Pb Ratio | 3.65 | 1.82 | 3.84 | 1.52 | 1.37 | 1.3 | |
| Ev To Sales | 18.33 | 25.67 | 17.58 | 7.08 | 8.14 | 7.73 | |
| Free Cash Flow Per Share | (0.0337) | (0.0178) | (0.0133) | (0.006603) | (0.005943) | (0.00624) | |
| Roic | (2.51) | (1.75) | (0.73) | (1.53) | (1.02) | (1.18) | |
| Net Income Per Share | (0.0413) | (0.0228) | (0.0129) | (0.005971) | (0.005374) | (0.005643) | |
| Sales General And Administrative To Revenue | 3.87 | 4.51 | 3.88 | 3.98 | 4.57 | 6.64 | |
| Research And Ddevelopement To Revenue | 15.66 | 11.55 | 9.58 | 8.05 | 9.26 | 12.84 | |
| Capex To Revenue | 0.0341 | 0.0129 | 0.0111 | 0.002692 | 0.003096 | 0.002941 | |
| Cash Per Share | 0.0233 | 0.0346 | 0.009781 | 0.006978 | 0.008025 | 0.007624 | |
| Pocfratio | (1.84) | (2.65) | (1.59) | (1.13) | (1.01) | (1.06) | |
| Interest Coverage | (38.95) | (713.44) | (131.12) | (585.36) | (526.82) | (500.48) | |
| Capex To Operating Cash Flow | (0.002155) | (0.001116) | (8.33E-4) | (2.37E-4) | (2.13E-4) | (2.24E-4) | |
| Pfcf Ratio | (1.83) | (2.65) | (1.59) | (1.13) | (1.01) | (1.06) | |
| Income Quality | 0.84 | 0.78 | 1.06 | 1.11 | 1.0 | 0.8 | |
| Roe | (2.44) | (0.88) | (2.36) | (1.22) | (1.41) | (1.48) | |
| Ev To Operating Cash Flow | (0.62) | (1.16) | (2.22) | (1.32) | (0.56) | (0.59) | |
| Pe Ratio | (1.5) | (2.08) | (1.63) | (1.24) | (1.12) | (1.18) | |
| Return On Tangible Assets | (1.55) | (0.62) | (1.13) | (0.76) | (0.69) | (0.72) | |
| Ev To Free Cash Flow | (0.62) | (1.16) | (2.22) | (1.32) | (0.56) | (0.59) | |
| Earnings Yield | (0.67) | (0.48) | (0.61) | (0.8) | (0.92) | (0.88) | |
| Net Debt To E B I T D A | 0.22 | 0.58 | 0.33 | 0.29 | 0.6 | 0.78 | |
| Current Ratio | 7.41 | 7.35 | 3.66 | 4.9 | 4.41 | 3.69 | |
| Tangible Book Value Per Share | 0.0169 | 0.026 | 0.005482 | 0.004883 | 0.005615 | 0.005335 | |
| Shareholders Equity Per Share | 0.0169 | 0.026 | 0.005482 | 0.004883 | 0.005615 | 0.005335 | |
| Debt To Equity | 0.011 | 0.008622 | 0.0139 | 0.006407 | 0.007368 | 0.007 | |
| Capex Per Share | 8.48E-4 | 3.5E-5 | 7.3E-5 | 2.0E-5 | 1.1E-5 | 2.0E-6 | |
| Graham Net Net | 0.0136 | 0.024 | 0.003903 | 0.004048 | 0.004656 | 0.004423 | |
| Revenue Per Share | 0.002129 | 0.001542 | 9.93E-4 | 5.81E-4 | 6.68E-4 | 6.35E-4 | |
| Interest Debt Per Share | 0.0012 | 2.57E-4 | 1.7E-4 | 4.2E-5 | 4.9E-5 | 4.6E-5 |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.